#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Brain Activity and Connectivity in Response to Negative Affective Stimuli: Impact of Dysphoric Mood and Sex Across Diagnoses Negative affective stimuli elicit behavioral and neural responses which vary on a continuum from adaptive to maladaptive, yet are typically investigated in a dichotomous manner (healthy controls vs. psychiatric diagnoses).
1-1	0-5	Brain	_
1-2	6-14	Activity	_
1-3	15-18	and	_
1-4	19-31	Connectivity	_
1-5	32-34	in	_
1-6	35-43	Response	_
1-7	44-46	to	_
1-8	47-55	Negative	_
1-9	56-65	Affective	_
1-10	66-73	Stimuli	_
1-11	74-75	:	_
1-12	76-82	Impact	_
1-13	83-85	of	_
1-14	86-95	Dysphoric	_
1-15	96-100	Mood	_
1-16	101-104	and	_
1-17	105-108	Sex	_
1-18	109-115	Across	_
1-19	116-125	Diagnoses	_
1-20	126-134	Negative	_
1-21	135-144	affective	_
1-22	145-152	stimuli	_
1-23	153-159	elicit	_
1-24	160-170	behavioral	_
1-25	171-174	and	_
1-26	175-181	neural	_
1-27	182-191	responses	_
1-28	192-197	which	_
1-29	198-202	vary	_
1-30	203-205	on	_
1-31	206-207	a	_
1-32	208-217	continuum	_
1-33	218-222	from	_
1-34	223-231	adaptive	_
1-35	232-234	to	_
1-36	235-246	maladaptive	_
1-37	247-248	,	_
1-38	249-252	yet	_
1-39	253-256	are	_
1-40	257-266	typically	_
1-41	267-279	investigated	_
1-42	280-282	in	_
1-43	283-284	a	_
1-44	285-296	dichotomous	_
1-45	297-303	manner	_
1-46	304-305	(	_
1-47	306-313	healthy	_
1-48	314-322	controls	_
1-49	323-326	vs.	_
1-50	327-338	psychiatric	_
1-51	339-348	diagnoses	_
1-52	349-350	)	_
1-53	351-352	.	_

Text=This practice may limit our ability to fully capture variance from acute responses to negative affective stimuli to psychopathology at the extreme end.
2-1	353-357	This	_
2-2	358-366	practice	_
2-3	367-370	may	_
2-4	371-376	limit	_
2-5	377-380	our	_
2-6	381-388	ability	_
2-7	389-391	to	_
2-8	392-397	fully	_
2-9	398-405	capture	_
2-10	406-414	variance	_
2-11	415-419	from	_
2-12	420-425	acute	_
2-13	426-435	responses	_
2-14	436-438	to	_
2-15	439-447	negative	_
2-16	448-457	affective	_
2-17	458-465	stimuli	_
2-18	466-468	to	_
2-19	469-484	psychopathology	_
2-20	485-487	at	_
2-21	488-491	the	_
2-22	492-499	extreme	_
2-23	500-503	end	_
2-24	504-505	.	_

Text=To address this, we conducted a functional magnetic resonance imaging (fMRI) study to examine the neural responses to negative valence/high arousal and neutral valence/low arousal images as a function of dysphoric mood and sex across individuals (n=99) who represented traditional categories of healthy controls, major depressive disorder, bipolar psychosis, and schizophrenia.
3-1	506-508	To	_
3-2	509-516	address	_
3-3	517-521	this	_
3-4	522-523	,	_
3-5	524-526	we	_
3-6	527-536	conducted	_
3-7	537-538	a	_
3-8	539-549	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-9	550-558	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-10	559-568	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-11	569-576	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-12	577-578	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-13	579-583	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-14	584-585	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
3-15	586-591	study	_
3-16	592-594	to	_
3-17	595-602	examine	_
3-18	603-606	the	_
3-19	607-613	neural	_
3-20	614-623	responses	_
3-21	624-626	to	_
3-22	627-635	negative	_
3-23	636-648	valence/high	_
3-24	649-656	arousal	_
3-25	657-660	and	_
3-26	661-668	neutral	_
3-27	669-680	valence/low	_
3-28	681-688	arousal	_
3-29	689-695	images	_
3-30	696-698	as	_
3-31	699-700	a	_
3-32	701-709	function	_
3-33	710-712	of	_
3-34	713-722	dysphoric	_
3-35	723-727	mood	_
3-36	728-731	and	_
3-37	732-735	sex	_
3-38	736-742	across	_
3-39	743-754	individuals	_
3-40	755-756	(	_
3-41	757-761	n=99	_
3-42	762-763	)	_
3-43	764-767	who	_
3-44	768-779	represented	_
3-45	780-791	traditional	_
3-46	792-802	categories	_
3-47	803-805	of	_
3-48	806-813	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-49	814-822	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-50	823-824	,	_
3-51	825-830	major	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
3-52	831-841	depressive	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
3-53	842-850	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
3-54	851-852	,	_
3-55	853-860	bipolar	_
3-56	861-870	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
3-57	871-872	,	_
3-58	873-876	and	_
3-59	877-890	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-60	891-892	.	_

Text=Observation of negative (vs. neutral) stimuli elicited BOLD responses in the following circuitry: periaqueductal gray [PAG], hypothalamus [HYPO], amygdala [AMYG], hippocampus [HIPP], orbitofrontal cortex [OFC], medial prefrontal cortex [mPFC], and greater connectivity between AMYG and mPFC.
4-1	893-904	Observation	_
4-2	905-907	of	_
4-3	908-916	negative	_
4-4	917-918	(	_
4-5	919-922	vs.	_
4-6	923-930	neutral	_
4-7	931-932	)	_
4-8	933-940	stimuli	_
4-9	941-949	elicited	_
4-10	950-954	BOLD	_
4-11	955-964	responses	_
4-12	965-967	in	_
4-13	968-971	the	_
4-14	972-981	following	_
4-15	982-991	circuitry	_
4-16	992-993	:	_
4-17	994-1008	periaqueductal	_
4-18	1009-1013	gray	_
4-19	1014-1015	[	_
4-20	1016-1019	PAG	_
4-21	1020-1021	]	_
4-22	1022-1023	,	_
4-23	1024-1036	hypothalamus	_
4-24	1037-1038	[	_
4-25	1039-1043	HYPO	_
4-26	1044-1045	]	_
4-27	1046-1047	,	_
4-28	1048-1056	amygdala	_
4-29	1057-1058	[	_
4-30	1059-1063	AMYG	_
4-31	1064-1065	]	_
4-32	1066-1067	,	_
4-33	1068-1079	hippocampus	_
4-34	1080-1081	[	_
4-35	1082-1086	HIPP	_
4-36	1087-1088	]	_
4-37	1089-1090	,	_
4-38	1091-1104	orbitofrontal	_
4-39	1105-1111	cortex	_
4-40	1112-1113	[	_
4-41	1114-1117	OFC	_
4-42	1118-1119	]	_
4-43	1120-1121	,	_
4-44	1122-1128	medial	_
4-45	1129-1139	prefrontal	_
4-46	1140-1146	cortex	_
4-47	1147-1148	[	_
4-48	1149-1153	mPFC	_
4-49	1154-1155	]	_
4-50	1156-1157	,	_
4-51	1158-1161	and	_
4-52	1162-1169	greater	_
4-53	1170-1182	connectivity	_
4-54	1183-1190	between	_
4-55	1191-1195	AMYG	_
4-56	1196-1199	and	_
4-57	1200-1204	mPFC	_
4-58	1205-1206	.	_

Text=Across all subjects, severity of dysphoric mood was associated with hyperactivity of HYPO, and, among females, right (R) AMYG.
5-1	1207-1213	Across	_
5-2	1214-1217	all	_
5-3	1218-1226	subjects	_
5-4	1227-1228	,	_
5-5	1229-1237	severity	_
5-6	1238-1240	of	_
5-7	1241-1250	dysphoric	_
5-8	1251-1255	mood	_
5-9	1256-1259	was	_
5-10	1260-1270	associated	_
5-11	1271-1275	with	_
5-12	1276-1289	hyperactivity	_
5-13	1290-1292	of	_
5-14	1293-1297	HYPO	_
5-15	1298-1299	,	_
5-16	1300-1303	and	_
5-17	1304-1305	,	_
5-18	1306-1311	among	_
5-19	1312-1319	females	_
5-20	1320-1321	,	_
5-21	1322-1327	right	_
5-22	1328-1329	(	_
5-23	1330-1331	R	_
5-24	1332-1333	)	_
5-25	1334-1338	AMYG	_
5-26	1339-1340	.	_

Text=Females also demonstrated inverse relationships between severity of dysphoric mood and connectivity between HYPO - R OFC, R AMYG - R OFC, and R AMYG - R HIPP.
6-1	1341-1348	Females	_
6-2	1349-1353	also	_
6-3	1354-1366	demonstrated	_
6-4	1367-1374	inverse	_
6-5	1375-1388	relationships	_
6-6	1389-1396	between	_
6-7	1397-1405	severity	_
6-8	1406-1408	of	_
6-9	1409-1418	dysphoric	_
6-10	1419-1423	mood	_
6-11	1424-1427	and	_
6-12	1428-1440	connectivity	_
6-13	1441-1448	between	_
6-14	1449-1453	HYPO	_
6-15	1454-1455	-	_
6-16	1456-1457	R	_
6-17	1458-1461	OFC	_
6-18	1462-1463	,	_
6-19	1464-1465	R	_
6-20	1466-1470	AMYG	_
6-21	1471-1472	-	_
6-22	1473-1474	R	_
6-23	1475-1478	OFC	_
6-24	1479-1480	,	_
6-25	1481-1484	and	_
6-26	1485-1486	R	_
6-27	1487-1491	AMYG	_
6-28	1492-1493	-	_
6-29	1494-1495	R	_
6-30	1496-1500	HIPP	_
6-31	1501-1502	.	_

Text=Overall, our findings demonstrated sex-dependent deficits in response to negative affective stimuli increasing as a function of dysphoric mood state.
7-1	1503-1510	Overall	_
7-2	1511-1512	,	_
7-3	1513-1516	our	_
7-4	1517-1525	findings	_
7-5	1526-1538	demonstrated	_
7-6	1539-1552	sex-dependent	_
7-7	1553-1561	deficits	_
7-8	1562-1564	in	_
7-9	1565-1573	response	_
7-10	1574-1576	to	_
7-11	1577-1585	negative	_
7-12	1586-1595	affective	_
7-13	1596-1603	stimuli	_
7-14	1604-1614	increasing	_
7-15	1615-1617	as	_
7-16	1618-1619	a	_
7-17	1620-1628	function	_
7-18	1629-1631	of	_
7-19	1632-1641	dysphoric	_
7-20	1642-1646	mood	_
7-21	1647-1652	state	_
7-22	1653-1654	.	_

Text=Females demonstrated greater inability to regulate arousal as mood became more dysphoric.
8-1	1655-1662	Females	_
8-2	1663-1675	demonstrated	_
8-3	1676-1683	greater	_
8-4	1684-1693	inability	_
8-5	1694-1696	to	_
8-6	1697-1705	regulate	_
8-7	1706-1713	arousal	_
8-8	1714-1716	as	_
8-9	1717-1721	mood	_
8-10	1722-1728	became	_
8-11	1729-1733	more	_
8-12	1734-1743	dysphoric	_
8-13	1744-1745	.	_

Text=These findings contribute to elucidating biosignatures associated with response to negative stimuli across disorders and suggest the importance of a sex-dependent lens in determining these biosignatures.
9-1	1746-1751	These	_
9-2	1752-1760	findings	_
9-3	1761-1771	contribute	_
9-4	1772-1774	to	_
9-5	1775-1786	elucidating	_
9-6	1787-1800	biosignatures	_
9-7	1801-1811	associated	_
9-8	1812-1816	with	_
9-9	1817-1825	response	_
9-10	1826-1828	to	_
9-11	1829-1837	negative	_
9-12	1838-1845	stimuli	_
9-13	1846-1852	across	_
9-14	1853-1862	disorders	_
9-15	1863-1866	and	_
9-16	1867-1874	suggest	_
9-17	1875-1878	the	_
9-18	1879-1889	importance	_
9-19	1890-1892	of	_
9-20	1893-1894	a	_
9-21	1895-1908	sex-dependent	_
9-22	1909-1913	lens	_
9-23	1914-1916	in	_
9-24	1917-1928	determining	_
9-25	1929-1934	these	_
9-26	1935-1948	biosignatures	_
9-27	1949-1950	.	_

Text=METHODS AND MATERIALS Participants Ninety-nine adults (51 males) participated in this study.
10-1	1951-1958	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	1959-1962	AND	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1963-1972	MATERIALS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1973-1985	Participants	_
10-5	1986-1997	Ninety-nine	_
10-6	1998-2004	adults	_
10-7	2005-2006	(	_
10-8	2007-2009	51	_
10-9	2010-2015	males	_
10-10	2016-2017	)	_
10-11	2018-2030	participated	_
10-12	2031-2033	in	_
10-13	2034-2038	this	_
10-14	2039-2044	study	_
10-15	2045-2046	.	_

Text=The majority were offspring of women who took part in the large scale (n=17 741) Boston and Providence Collaborative Perinatal Project ([CPP], adult offspring whom we have been following for about 20 years in the New England Family Studies [NEFS].
11-1	2047-2050	The	_
11-2	2051-2059	majority	_
11-3	2060-2064	were	_
11-4	2065-2074	offspring	_
11-5	2075-2077	of	_
11-6	2078-2083	women	_
11-7	2084-2087	who	_
11-8	2088-2092	took	_
11-9	2093-2097	part	_
11-10	2098-2100	in	_
11-11	2101-2104	the	_
11-12	2105-2110	large	_
11-13	2111-2116	scale	_
11-14	2117-2118	(	_
11-15	2119-2123	n=17	_
11-16	2124-2127	741	_
11-17	2128-2129	)	_
11-18	2130-2136	Boston	_
11-19	2137-2140	and	_
11-20	2141-2151	Providence	_
11-21	2152-2165	Collaborative	_
11-22	2166-2175	Perinatal	_
11-23	2176-2183	Project	_
11-24	2184-2185	(	_
11-25	2186-2187	[	_
11-26	2188-2191	CPP	_
11-27	2192-2193	]	_
11-28	2194-2195	,	_
11-29	2196-2201	adult	_
11-30	2202-2211	offspring	_
11-31	2212-2216	whom	_
11-32	2217-2219	we	_
11-33	2220-2224	have	_
11-34	2225-2229	been	_
11-35	2230-2239	following	_
11-36	2240-2243	for	_
11-37	2244-2249	about	_
11-38	2250-2252	20	_
11-39	2253-2258	years	_
11-40	2259-2261	in	_
11-41	2262-2265	the	_
11-42	2266-2269	New	_
11-43	2270-2277	England	_
11-44	2278-2284	Family	_
11-45	2285-2292	Studies	_
11-46	2293-2294	[	_
11-47	2295-2299	NEFS	_
11-48	2300-2301	]	_
11-49	2302-2303	.	_

Text=Approximately 14% were non-NEFS subjects but recruited using the same criteria, from the same community catchment area and not different on any sociodemographic or clinical characteristic than the rest of the sample.
12-1	2304-2317	Approximately	_
12-2	2318-2320	14	_
12-3	2321-2322	%	_
12-4	2323-2327	were	_
12-5	2328-2336	non-NEFS	_
12-6	2337-2345	subjects	_
12-7	2346-2349	but	_
12-8	2350-2359	recruited	_
12-9	2360-2365	using	_
12-10	2366-2369	the	_
12-11	2370-2374	same	_
12-12	2375-2383	criteria	_
12-13	2384-2385	,	_
12-14	2386-2390	from	_
12-15	2391-2394	the	_
12-16	2395-2399	same	_
12-17	2400-2409	community	_
12-18	2410-2419	catchment	_
12-19	2420-2424	area	_
12-20	2425-2428	and	_
12-21	2429-2432	not	_
12-22	2433-2442	different	_
12-23	2443-2445	on	_
12-24	2446-2449	any	_
12-25	2450-2466	sociodemographic	_
12-26	2467-2469	or	_
12-27	2470-2478	clinical	_
12-28	2479-2493	characteristic	_
12-29	2494-2498	than	_
12-30	2499-2502	the	_
12-31	2503-2507	rest	_
12-32	2508-2510	of	_
12-33	2511-2514	the	_
12-34	2515-2521	sample	_
12-35	2522-2523	.	_

Text=Fifteen individuals were diagnosed with non-affective psychosis including schizophrenia, schizoaffective-depressed type, and psychosis not otherwise specified (SCZ; 9 males), 16 individuals with affective psychosis including bipolar disorder with psychosis and schizoaffective disorder-bipolar type (BP; 7 males), 27 with recurrent major depressive disorder without psychosis (MDD; 13 males), and 41 were healthy controls (CTRL; 22 males).
13-1	2524-2531	Fifteen	_
13-2	2532-2543	individuals	_
13-3	2544-2548	were	_
13-4	2549-2558	diagnosed	_
13-5	2559-2563	with	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
13-6	2564-2577	non-affective	_
13-7	2578-2587	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
13-8	2588-2597	including	_
13-9	2598-2611	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-10	2612-2613	,	_
13-11	2614-2639	schizoaffective-depressed	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
13-12	2640-2644	type	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
13-13	2645-2646	,	_
13-14	2647-2650	and	_
13-15	2651-2660	psychosis	_
13-16	2661-2664	not	_
13-17	2665-2674	otherwise	_
13-18	2675-2684	specified	_
13-19	2685-2686	(	_
13-20	2687-2690	SCZ	_
13-21	2691-2692	;	_
13-22	2693-2694	9	_
13-23	2695-2700	males	_
13-24	2701-2702	)	_
13-25	2703-2704	,	_
13-26	2705-2707	16	_
13-27	2708-2719	individuals	_
13-28	2720-2724	with	http://maven.renci.org/NeuroBridge/neurobridge#MixedBipolarAffectiveDisorder
13-29	2725-2734	affective	http://maven.renci.org/NeuroBridge/neurobridge#MixedBipolarAffectiveDisorder
13-30	2735-2744	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#MixedBipolarAffectiveDisorder
13-31	2745-2754	including	_
13-32	2755-2762	bipolar	_
13-33	2763-2771	disorder	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
13-34	2772-2776	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
13-35	2777-2786	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
13-36	2787-2790	and	_
13-37	2791-2806	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
13-38	2807-2823	disorder-bipolar	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
13-39	2824-2828	type	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
13-40	2829-2830	(	_
13-41	2831-2833	BP	_
13-42	2834-2835	;	_
13-43	2836-2837	7	_
13-44	2838-2843	males	_
13-45	2844-2845	)	_
13-46	2846-2847	,	_
13-47	2848-2850	27	_
13-48	2851-2855	with	_
13-49	2856-2865	recurrent	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
13-50	2866-2871	major	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
13-51	2872-2882	depressive	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
13-52	2883-2891	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
13-53	2892-2899	without	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
13-54	2900-2909	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
13-55	2910-2911	(	_
13-56	2912-2915	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
13-57	2916-2917	;	_
13-58	2918-2920	13	_
13-59	2921-2926	males	_
13-60	2927-2928	)	_
13-61	2929-2930	,	_
13-62	2931-2934	and	_
13-63	2935-2937	41	_
13-64	2938-2942	were	_
13-65	2943-2950	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-66	2951-2959	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-67	2960-2961	(	_
13-68	2962-2966	CTRL	http://maven.renci.org/NeuroBridge/neurobridge#Spectroscopy
13-69	2967-2968	;	_
13-70	2969-2971	22	_
13-71	2972-2977	males	_
13-72	2978-2979	)	_
13-73	2980-2981	.	_

Text=These PSY classifications have a long history and validation in family studies and have been used in our population-level NEFS studies over many years.
14-1	2982-2987	These	_
14-2	2988-2991	PSY	_
14-3	2992-3007	classifications	_
14-4	3008-3012	have	_
14-5	3013-3014	a	_
14-6	3015-3019	long	_
14-7	3020-3027	history	_
14-8	3028-3031	and	_
14-9	3032-3042	validation	_
14-10	3043-3045	in	_
14-11	3046-3052	family	_
14-12	3053-3060	studies	_
14-13	3061-3064	and	_
14-14	3065-3069	have	_
14-15	3070-3074	been	_
14-16	3075-3079	used	_
14-17	3080-3082	in	_
14-18	3083-3086	our	_
14-19	3087-3103	population-level	_
14-20	3104-3108	NEFS	_
14-21	3109-3116	studies	_
14-22	3117-3121	over	_
14-23	3122-3126	many	_
14-24	3127-3132	years	_
14-25	3133-3134	.	_

Text=Individuals with either MDD or SCZ were not currently in an episode (no clinically-significant depressive symptoms in the MDD group; no active psychosis in the SCZ group).
15-1	3135-3146	Individuals	_
15-2	3147-3151	with	_
15-3	3152-3158	either	_
15-4	3159-3162	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
15-5	3163-3165	or	_
15-6	3166-3169	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-7	3170-3174	were	_
15-8	3175-3178	not	_
15-9	3179-3188	currently	_
15-10	3189-3191	in	_
15-11	3192-3194	an	_
15-12	3195-3202	episode	_
15-13	3203-3204	(	_
15-14	3205-3207	no	_
15-15	3208-3230	clinically-significant	_
15-16	3231-3241	depressive	_
15-17	3242-3250	symptoms	_
15-18	3251-3253	in	_
15-19	3254-3257	the	_
15-20	3258-3261	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
15-21	3262-3267	group	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
15-22	3268-3269	;	_
15-23	3270-3272	no	_
15-24	3273-3279	active	_
15-25	3280-3289	psychosis	_
15-26	3290-3292	in	_
15-27	3293-3296	the	_
15-28	3297-3300	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-29	3301-3306	group	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-30	3307-3308	)	_
15-31	3309-3310	.	_

Text=As described in Jacobs et al (2015), women were scanned on two occasions - “ low E2 “ and “ high E2 “ conditions, categorized based on the relative change in 17β-estradiol (E2) between two scanning visits (during early follicular and late follicular/midcycle).
16-1	3311-3313	As	_
16-2	3314-3323	described	_
16-3	3324-3326	in	_
16-4	3327-3333	Jacobs	_
16-5	3334-3336	et	_
16-6	3337-3339	al	_
16-7	3340-3341	(	_
16-8	3342-3346	2015	_
16-9	3347-3348	)	_
16-10	3349-3350	,	_
16-11	3351-3356	women	_
16-12	3357-3361	were	_
16-13	3362-3369	scanned	_
16-14	3370-3372	on	_
16-15	3373-3376	two	_
16-16	3377-3386	occasions	_
16-17	3387-3388	-	_
16-18	3389-3390	“	_
16-19	3391-3394	low	_
16-20	3395-3397	E2	_
16-21	3398-3399	“	_
16-22	3400-3403	and	_
16-23	3404-3405	“	_
16-24	3406-3410	high	_
16-25	3411-3413	E2	_
16-26	3414-3415	“	_
16-27	3416-3426	conditions	_
16-28	3427-3428	,	_
16-29	3429-3440	categorized	_
16-30	3441-3446	based	_
16-31	3447-3449	on	_
16-32	3450-3453	the	_
16-33	3454-3462	relative	_
16-34	3463-3469	change	_
16-35	3470-3472	in	_
16-36	3473-3486	17β-estradiol	_
16-37	3487-3488	(	_
16-38	3489-3491	E2	_
16-39	3492-3493	)	_
16-40	3494-3501	between	_
16-41	3502-3505	two	_
16-42	3506-3514	scanning	_
16-43	3515-3521	visits	_
16-44	3522-3523	(	_
16-45	3524-3530	during	_
16-46	3531-3536	early	_
16-47	3537-3547	follicular	_
16-48	3548-3551	and	_
16-49	3552-3556	late	_
16-50	3557-3576	follicular/midcycle	_
16-51	3577-3578	)	_
16-52	3579-3580	.	_

Text=In our previous work with this task, we demonstrated more substantial sex differences in brain activity in our circuitry of interest for women during late follicular/midcyle versus men in comparison to the same women scanned during the early follicular menstrual phases versus men.
17-1	3581-3583	In	_
17-2	3584-3587	our	_
17-3	3588-3596	previous	_
17-4	3597-3601	work	_
17-5	3602-3606	with	_
17-6	3607-3611	this	_
17-7	3612-3616	task	_
17-8	3617-3618	,	_
17-9	3619-3621	we	_
17-10	3622-3634	demonstrated	_
17-11	3635-3639	more	_
17-12	3640-3651	substantial	_
17-13	3652-3655	sex	_
17-14	3656-3667	differences	_
17-15	3668-3670	in	_
17-16	3671-3676	brain	_
17-17	3677-3685	activity	_
17-18	3686-3688	in	_
17-19	3689-3692	our	_
17-20	3693-3702	circuitry	_
17-21	3703-3705	of	_
17-22	3706-3714	interest	_
17-23	3715-3718	for	_
17-24	3719-3724	women	_
17-25	3725-3731	during	_
17-26	3732-3736	late	_
17-27	3737-3755	follicular/midcyle	_
17-28	3756-3762	versus	_
17-29	3763-3766	men	_
17-30	3767-3769	in	_
17-31	3770-3780	comparison	_
17-32	3781-3783	to	_
17-33	3784-3787	the	_
17-34	3788-3792	same	_
17-35	3793-3798	women	_
17-36	3799-3806	scanned	_
17-37	3807-3813	during	_
17-38	3814-3817	the	_
17-39	3818-3823	early	_
17-40	3824-3834	follicular	_
17-41	3835-3844	menstrual	_
17-42	3845-3851	phases	_
17-43	3852-3858	versus	_
17-44	3859-3862	men	_
17-45	3863-3864	.	_

Text=This is consistent with others who demonstrated that sensitivity to negative affect differed across menstrual cycle phase.
18-1	3865-3869	This	_
18-2	3870-3872	is	_
18-3	3873-3883	consistent	_
18-4	3884-3888	with	_
18-5	3889-3895	others	_
18-6	3896-3899	who	_
18-7	3900-3912	demonstrated	_
18-8	3913-3917	that	_
18-9	3918-3929	sensitivity	_
18-10	3930-3932	to	_
18-11	3933-3941	negative	_
18-12	3942-3948	affect	_
18-13	3949-3957	differed	_
18-14	3958-3964	across	_
18-15	3965-3974	menstrual	_
18-16	3975-3980	cycle	_
18-17	3981-3986	phase	_
18-18	3987-3988	.	_

Text=Thus, in the analyses here, we included data from women scanned under “ high E2 “ only, thus eliminating a potential confound among the women with respect to brain activity in AMYG, HIPP and HYPO in response to negative affective stimuli.
19-1	3989-3993	Thus	_
19-2	3994-3995	,	_
19-3	3996-3998	in	_
19-4	3999-4002	the	_
19-5	4003-4011	analyses	_
19-6	4012-4016	here	_
19-7	4017-4018	,	_
19-8	4019-4021	we	_
19-9	4022-4030	included	_
19-10	4031-4035	data	_
19-11	4036-4040	from	_
19-12	4041-4046	women	_
19-13	4047-4054	scanned	_
19-14	4055-4060	under	_
19-15	4061-4062	“	_
19-16	4063-4067	high	_
19-17	4068-4070	E2	_
19-18	4071-4072	“	_
19-19	4073-4077	only	_
19-20	4078-4079	,	_
19-21	4080-4084	thus	_
19-22	4085-4096	eliminating	_
19-23	4097-4098	a	_
19-24	4099-4108	potential	_
19-25	4109-4117	confound	_
19-26	4118-4123	among	_
19-27	4124-4127	the	_
19-28	4128-4133	women	_
19-29	4134-4138	with	_
19-30	4139-4146	respect	_
19-31	4147-4149	to	_
19-32	4150-4155	brain	_
19-33	4156-4164	activity	_
19-34	4165-4167	in	_
19-35	4168-4172	AMYG	_
19-36	4173-4174	,	_
19-37	4175-4179	HIPP	_
19-38	4180-4183	and	_
19-39	4184-4188	HYPO	_
19-40	4189-4191	in	_
19-41	4192-4200	response	_
19-42	4201-4203	to	_
19-43	4204-4212	negative	_
19-44	4213-4222	affective	_
19-45	4223-4230	stimuli	_
19-46	4231-4232	.	_

Text=The mean baseline levels of estradiol were 102.88 pg/mL (SD=74.95 pg/mL), which did not differ after exposure to the negative affective images.
20-1	4233-4236	The	_
20-2	4237-4241	mean	_
20-3	4242-4250	baseline	_
20-4	4251-4257	levels	_
20-5	4258-4260	of	_
20-6	4261-4270	estradiol	_
20-7	4271-4275	were	_
20-8	4276-4282	102.88	_
20-9	4283-4288	pg/mL	_
20-10	4289-4290	(	_
20-11	4291-4299	SD=74.95	_
20-12	4300-4305	pg/mL	_
20-13	4306-4307	)	_
20-14	4308-4309	,	_
20-15	4310-4315	which	_
20-16	4316-4319	did	_
20-17	4320-4323	not	_
20-18	4324-4330	differ	_
20-19	4331-4336	after	_
20-20	4337-4345	exposure	_
20-21	4346-4348	to	_
20-22	4349-4352	the	_
20-23	4353-4361	negative	_
20-24	4362-4371	affective	_
20-25	4372-4378	images	_
20-26	4379-4380	.	_

Text=Demographics and clinical characteristics of the sample are in Table 1.
21-1	4381-4393	Demographics	_
21-2	4394-4397	and	_
21-3	4398-4406	clinical	_
21-4	4407-4422	characteristics	_
21-5	4423-4425	of	_
21-6	4426-4429	the	_
21-7	4430-4436	sample	_
21-8	4437-4440	are	_
21-9	4441-4443	in	_
21-10	4444-4449	Table	_
21-11	4450-4451	1	_
21-12	4452-4453	.	_

Text=All participants provided written informed consent to a protocol approved by Harvard University, Brown University, Partners Healthcare system, and local psychiatric facilities.
22-1	4454-4457	All	_
22-2	4458-4470	participants	_
22-3	4471-4479	provided	_
22-4	4480-4487	written	_
22-5	4488-4496	informed	_
22-6	4497-4504	consent	_
22-7	4505-4507	to	_
22-8	4508-4509	a	_
22-9	4510-4518	protocol	_
22-10	4519-4527	approved	_
22-11	4528-4530	by	_
22-12	4531-4538	Harvard	_
22-13	4539-4549	University	_
22-14	4550-4551	,	_
22-15	4552-4557	Brown	_
22-16	4558-4568	University	_
22-17	4569-4570	,	_
22-18	4571-4579	Partners	_
22-19	4580-4590	Healthcare	_
22-20	4591-4597	system	_
22-21	4598-4599	,	_
22-22	4600-4603	and	_
22-23	4604-4609	local	_
22-24	4610-4621	psychiatric	_
22-25	4622-4632	facilities	_
22-26	4633-4634	.	_

Text=There were no differences between men and women in ethnicity, handedness, age, body mass index, parental SES, educational level, WAIS-R vocabulary scores, rate of DSM diagnoses, or use of psychotropic medications.
23-1	4635-4640	There	_
23-2	4641-4645	were	_
23-3	4646-4648	no	_
23-4	4649-4660	differences	_
23-5	4661-4668	between	_
23-6	4669-4672	men	_
23-7	4673-4676	and	_
23-8	4677-4682	women	_
23-9	4683-4685	in	_
23-10	4686-4695	ethnicity	_
23-11	4696-4697	,	_
23-12	4698-4708	handedness	_
23-13	4709-4710	,	_
23-14	4711-4714	age	_
23-15	4715-4716	,	_
23-16	4717-4721	body	_
23-17	4722-4726	mass	_
23-18	4727-4732	index	_
23-19	4733-4734	,	_
23-20	4735-4743	parental	_
23-21	4744-4747	SES	_
23-22	4748-4749	,	_
23-23	4750-4761	educational	_
23-24	4762-4767	level	_
23-25	4768-4769	,	_
23-26	4770-4776	WAIS-R	_
23-27	4777-4787	vocabulary	_
23-28	4788-4794	scores	_
23-29	4795-4796	,	_
23-30	4797-4801	rate	_
23-31	4802-4804	of	_
23-32	4805-4808	DSM	_
23-33	4809-4818	diagnoses	_
23-34	4819-4820	,	_
23-35	4821-4823	or	_
23-36	4824-4827	use	_
23-37	4828-4830	of	_
23-38	4831-4843	psychotropic	_
23-39	4844-4855	medications	_
23-40	4856-4857	.	_

Text=Compared to women, men scored higher on the WAIS block design (F (2,93) =4.29, p=0.02; CTRL> PSY: p=0.02) and had a higher rate of substance abuse disorders (X2 (1, N=99) =21.80, p <0.0001).
24-1	4858-4866	Compared	_
24-2	4867-4869	to	_
24-3	4870-4875	women	_
24-4	4876-4877	,	_
24-5	4878-4881	men	_
24-6	4882-4888	scored	_
24-7	4889-4895	higher	_
24-8	4896-4898	on	_
24-9	4899-4902	the	_
24-10	4903-4907	WAIS	_
24-11	4908-4913	block	_
24-12	4914-4920	design	_
24-13	4921-4922	(	_
24-14	4923-4924	F	_
24-15	4925-4926	(	_
24-16	4927-4931	2,93	_
24-17	4932-4933	)	_
24-18	4934-4939	=4.29	_
24-19	4940-4941	,	_
24-20	4942-4948	p=0.02	_
24-21	4949-4950	;	_
24-22	4951-4955	CTRL	_
24-23	4956-4957	>	_
24-24	4958-4961	PSY	_
24-25	4962-4963	:	_
24-26	4964-4970	p=0.02	_
24-27	4971-4972	)	_
24-28	4973-4976	and	_
24-29	4977-4980	had	_
24-30	4981-4982	a	_
24-31	4983-4989	higher	_
24-32	4990-4994	rate	_
24-33	4995-4997	of	_
24-34	4998-5007	substance	_
24-35	5008-5013	abuse	_
24-36	5014-5023	disorders	_
24-37	5024-5025	(	_
24-38	5026-5028	X2	_
24-39	5029-5030	(	_
24-40	5031-5032	1	_
24-41	5033-5034	,	_
24-42	5035-5039	N=99	_
24-43	5040-5041	)	_
24-44	5042-5048	=21.80	_
24-45	5049-5050	,	_
24-46	5051-5052	p	_
24-47	5053-5054	<	_
24-48	5055-5061	0.0001	_
24-49	5062-5063	)	_
24-50	5064-5065	.	_

Text=Assessment of mood and anxiety Profile of Mood States (POMS) and State-Trait Anxiety Inventory (STAI), self-report questionnaires, were administered before the MRI scan to assess mood and anxiety.
25-1	5066-5076	Assessment	_
25-2	5077-5079	of	_
25-3	5080-5084	mood	_
25-4	5085-5088	and	_
25-5	5089-5096	anxiety	_
25-6	5097-5104	Profile	_
25-7	5105-5107	of	_
25-8	5108-5112	Mood	http://maven.renci.org/NeuroBridge/neurobridge#PhysiologicalState
25-9	5113-5119	States	http://maven.renci.org/NeuroBridge/neurobridge#PhysiologicalState
25-10	5120-5121	(	http://maven.renci.org/NeuroBridge/neurobridge#PhysiologicalState
25-11	5122-5126	POMS	http://maven.renci.org/NeuroBridge/neurobridge#PhysiologicalState
25-12	5127-5128	)	http://maven.renci.org/NeuroBridge/neurobridge#PhysiologicalState
25-13	5129-5132	and	_
25-14	5133-5144	State-Trait	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
25-15	5145-5152	Anxiety	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
25-16	5153-5162	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
25-17	5163-5164	(	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
25-18	5165-5169	STAI	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
25-19	5170-5171	)	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
25-20	5172-5173	,	_
25-21	5174-5185	self-report	_
25-22	5186-5200	questionnaires	_
25-23	5201-5202	,	_
25-24	5203-5207	were	_
25-25	5208-5220	administered	_
25-26	5221-5227	before	_
25-27	5228-5231	the	_
25-28	5232-5235	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
25-29	5236-5240	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
25-30	5241-5243	to	_
25-31	5244-5250	assess	_
25-32	5251-5255	mood	_
25-33	5256-5259	and	_
25-34	5260-5267	anxiety	_
25-35	5268-5269	.	_

Text=The POMS measured the degree to which each of 40 affective adjectives applied to current mood state (rated on a Likert-type scale from 0 to 4).
26-1	5270-5273	The	_
26-2	5274-5278	POMS	_
26-3	5279-5287	measured	_
26-4	5288-5291	the	_
26-5	5292-5298	degree	_
26-6	5299-5301	to	_
26-7	5302-5307	which	_
26-8	5308-5312	each	_
26-9	5313-5315	of	_
26-10	5316-5318	40	_
26-11	5319-5328	affective	_
26-12	5329-5339	adjectives	_
26-13	5340-5347	applied	_
26-14	5348-5350	to	_
26-15	5351-5358	current	_
26-16	5359-5363	mood	_
26-17	5364-5369	state	_
26-18	5370-5371	(	_
26-19	5372-5377	rated	_
26-20	5378-5380	on	_
26-21	5381-5382	a	_
26-22	5383-5394	Likert-type	_
26-23	5395-5400	scale	_
26-24	5401-5405	from	_
26-25	5406-5407	0	_
26-26	5408-5410	to	_
26-27	5411-5412	4	_
26-28	5413-5414	)	_
26-29	5415-5416	.	_

Text=The STAI measured anxiety-related symptoms using a 1 to 4 Likert-type scale, with two versions that differentiate “ state ” (“ How do you feel right now ”) and “ trait ” (“ How do you generally feel ”) anxiety.
27-1	5417-5420	The	_
27-2	5421-5425	STAI	http://maven.renci.org/NeuroBridge/neurobridge#Stadiometer
27-3	5426-5434	measured	_
27-4	5435-5450	anxiety-related	_
27-5	5451-5459	symptoms	_
27-6	5460-5465	using	_
27-7	5466-5467	a	_
27-8	5468-5469	1	_
27-9	5470-5472	to	_
27-10	5473-5474	4	_
27-11	5475-5486	Likert-type	_
27-12	5487-5492	scale	_
27-13	5493-5494	,	_
27-14	5495-5499	with	_
27-15	5500-5503	two	_
27-16	5504-5512	versions	_
27-17	5513-5517	that	_
27-18	5518-5531	differentiate	_
27-19	5532-5533	“	_
27-20	5534-5539	state	_
27-21	5540-5541	”	_
27-22	5542-5543	(	_
27-23	5544-5545	“	_
27-24	5546-5549	How	_
27-25	5550-5552	do	_
27-26	5553-5556	you	_
27-27	5557-5561	feel	_
27-28	5562-5567	right	_
27-29	5568-5571	now	_
27-30	5572-5573	”	_
27-31	5574-5575	)	_
27-32	5576-5579	and	_
27-33	5580-5581	“	_
27-34	5582-5587	trait	_
27-35	5588-5589	”	_
27-36	5590-5591	(	_
27-37	5592-5593	“	_
27-38	5594-5597	How	_
27-39	5598-5600	do	_
27-40	5601-5604	you	_
27-41	5605-5614	generally	_
27-42	5615-5619	feel	_
27-43	5620-5621	”	_
27-44	5622-5623	)	_
27-45	5624-5631	anxiety	_
27-46	5632-5633	.	_

Text=Dysphoric Mood State To create a composite measure of mood and anxiety current state and traits, the five POMS subscales (tension/anxiety [TA], depression/dejection [DD], anger/hostility [AH], fatigue/inertia [FI], vigor/activity [VA], confusion/bewilderment [CB]) and two STAI subscales (Anxiety State, Anxiety Trait) were factor analyzed using the maximum likelihood factor method and Varimax rotation.
28-1	5634-5643	Dysphoric	_
28-2	5644-5648	Mood	_
28-3	5649-5654	State	_
28-4	5655-5657	To	_
28-5	5658-5664	create	_
28-6	5665-5666	a	_
28-7	5667-5676	composite	_
28-8	5677-5684	measure	_
28-9	5685-5687	of	_
28-10	5688-5692	mood	_
28-11	5693-5696	and	_
28-12	5697-5704	anxiety	_
28-13	5705-5712	current	_
28-14	5713-5718	state	_
28-15	5719-5722	and	_
28-16	5723-5729	traits	_
28-17	5730-5731	,	_
28-18	5732-5735	the	_
28-19	5736-5740	five	_
28-20	5741-5745	POMS	_
28-21	5746-5755	subscales	_
28-22	5756-5757	(	_
28-23	5758-5773	tension/anxiety	_
28-24	5774-5775	[	_
28-25	5776-5778	TA	_
28-26	5779-5780	]	_
28-27	5781-5782	,	_
28-28	5783-5803	depression/dejection	_
28-29	5804-5805	[	_
28-30	5806-5808	DD	_
28-31	5809-5810	]	_
28-32	5811-5812	,	_
28-33	5813-5828	anger/hostility	_
28-34	5829-5830	[	_
28-35	5831-5833	AH	_
28-36	5834-5835	]	_
28-37	5836-5837	,	_
28-38	5838-5853	fatigue/inertia	_
28-39	5854-5855	[	_
28-40	5856-5858	FI	_
28-41	5859-5860	]	_
28-42	5861-5862	,	_
28-43	5863-5877	vigor/activity	_
28-44	5878-5879	[	_
28-45	5880-5882	VA	_
28-46	5883-5884	]	_
28-47	5885-5886	,	_
28-48	5887-5909	confusion/bewilderment	_
28-49	5910-5911	[	_
28-50	5912-5914	CB	_
28-51	5915-5916	]	_
28-52	5917-5918	)	_
28-53	5919-5922	and	_
28-54	5923-5926	two	_
28-55	5927-5931	STAI	_
28-56	5932-5941	subscales	_
28-57	5942-5943	(	_
28-58	5944-5951	Anxiety	_
28-59	5952-5957	State	_
28-60	5958-5959	,	_
28-61	5960-5967	Anxiety	_
28-62	5968-5973	Trait	_
28-63	5974-5975	)	_
28-64	5976-5980	were	_
28-65	5981-5987	factor	_
28-66	5988-5996	analyzed	_
28-67	5997-6002	using	_
28-68	6003-6006	the	_
28-69	6007-6014	maximum	_
28-70	6015-6025	likelihood	_
28-71	6026-6032	factor	_
28-72	6033-6039	method	_
28-73	6040-6043	and	_
28-74	6044-6051	Varimax	_
28-75	6052-6060	rotation	_
28-76	6061-6062	.	_

Text=The primary factor explaining the highest portion of variance reflected a clinical state of dysphoric feelings that we traditionally associate with depressed mood (see Supplementary Results).
29-1	6063-6066	The	_
29-2	6067-6074	primary	_
29-3	6075-6081	factor	_
29-4	6082-6092	explaining	_
29-5	6093-6096	the	_
29-6	6097-6104	highest	_
29-7	6105-6112	portion	_
29-8	6113-6115	of	_
29-9	6116-6124	variance	_
29-10	6125-6134	reflected	_
29-11	6135-6136	a	_
29-12	6137-6145	clinical	_
29-13	6146-6151	state	_
29-14	6152-6154	of	_
29-15	6155-6164	dysphoric	_
29-16	6165-6173	feelings	_
29-17	6174-6178	that	_
29-18	6179-6181	we	_
29-19	6182-6195	traditionally	_
29-20	6196-6205	associate	_
29-21	6206-6210	with	_
29-22	6211-6220	depressed	_
29-23	6221-6225	mood	_
29-24	6226-6227	(	_
29-25	6228-6231	see	_
29-26	6232-6245	Supplementary	_
29-27	6246-6253	Results	_
29-28	6254-6255	)	_
29-29	6256-6257	.	_

Text=We called this composite measure dysphoric mood state, in order to distinguish it from depression itself, given that we are measuring this clinical state across populations.
30-1	6258-6260	We	_
30-2	6261-6267	called	_
30-3	6268-6272	this	_
30-4	6273-6282	composite	_
30-5	6283-6290	measure	_
30-6	6291-6300	dysphoric	_
30-7	6301-6305	mood	_
30-8	6306-6311	state	_
30-9	6312-6313	,	_
30-10	6314-6316	in	_
30-11	6317-6322	order	_
30-12	6323-6325	to	_
30-13	6326-6337	distinguish	_
30-14	6338-6340	it	_
30-15	6341-6345	from	_
30-16	6346-6356	depression	_
30-17	6357-6363	itself	_
30-18	6364-6365	,	_
30-19	6366-6371	given	_
30-20	6372-6376	that	_
30-21	6377-6379	we	_
30-22	6380-6383	are	_
30-23	6384-6393	measuring	_
30-24	6394-6398	this	_
30-25	6399-6407	clinical	_
30-26	6408-6413	state	_
30-27	6414-6420	across	_
30-28	6421-6432	populations	_
30-29	6433-6434	.	_

Text=In subsequent fMRI analyses, it is used in associations with blood oxygen-level dependent (BOLD) brain activity responses and connectivity in our circuitry of interest.
31-1	6435-6437	In	_
31-2	6438-6448	subsequent	_
31-3	6449-6453	fMRI	_
31-4	6454-6462	analyses	_
31-5	6463-6464	,	_
31-6	6465-6467	it	_
31-7	6468-6470	is	_
31-8	6471-6475	used	_
31-9	6476-6478	in	_
31-10	6479-6491	associations	_
31-11	6492-6496	with	_
31-12	6497-6502	blood	_
31-13	6503-6515	oxygen-level	_
31-14	6516-6525	dependent	_
31-15	6526-6527	(	_
31-16	6528-6532	BOLD	_
31-17	6533-6534	)	_
31-18	6535-6540	brain	_
31-19	6541-6549	activity	_
31-20	6550-6559	responses	_
31-21	6560-6563	and	_
31-22	6564-6576	connectivity	_
31-23	6577-6579	in	_
31-24	6580-6583	our	_
31-25	6584-6593	circuitry	_
31-26	6594-6596	of	_
31-27	6597-6605	interest	_
31-28	6606-6607	.	_

Text=Acquisition of fMRI data fMRI data were acquired on a Siemens Tim Trio 3T MRI scanner with a 12-channel head coil.
32-1	6608-6619	Acquisition	_
32-2	6620-6622	of	_
32-3	6623-6627	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-4	6628-6632	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-5	6633-6637	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-6	6638-6642	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-7	6643-6647	were	_
32-8	6648-6656	acquired	_
32-9	6657-6659	on	_
32-10	6660-6661	a	_
32-11	6662-6669	Siemens	_
32-12	6670-6673	Tim	_
32-13	6674-6678	Trio	_
32-14	6679-6681	3T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
32-15	6682-6685	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
32-16	6686-6693	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
32-17	6694-6698	with	_
32-18	6699-6700	a	_
32-19	6701-6711	12-channel	_
32-20	6712-6716	head	_
32-21	6717-6721	coil	_
32-22	6722-6723	.	_

Text=A total of 180 volumes were acquired using a spin echo, T2 * -weighted sequence (TR=2000 ms, TE=40 ms, FOV=200x200 mm, matrix 64x64, in-plane resolution 3.125 mm, slice thickness 5 mm, 23 contiguous slices aligned to AC-PC plane).
33-1	6724-6725	A	_
33-2	6726-6731	total	_
33-3	6732-6734	of	_
33-4	6735-6738	180	_
33-5	6739-6746	volumes	_
33-6	6747-6751	were	_
33-7	6752-6760	acquired	_
33-8	6761-6766	using	_
33-9	6767-6768	a	_
33-10	6769-6773	spin	http://maven.renci.org/NeuroBridge/neurobridge#Spectroscopy
33-11	6774-6778	echo	http://maven.renci.org/NeuroBridge/neurobridge#Spectroscopy
33-12	6779-6780	,	http://maven.renci.org/NeuroBridge/neurobridge#Spectroscopy
33-13	6781-6783	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-14	6784-6785	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-15	6786-6795	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-16	6796-6804	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
33-17	6805-6806	(	_
33-18	6807-6814	TR=2000	_
33-19	6815-6817	ms	_
33-20	6818-6819	,	_
33-21	6820-6825	TE=40	_
33-22	6826-6828	ms	_
33-23	6829-6830	,	_
33-24	6831-6842	FOV=200x200	_
33-25	6843-6845	mm	_
33-26	6846-6847	,	_
33-27	6848-6854	matrix	_
33-28	6855-6860	64x64	_
33-29	6861-6862	,	_
33-30	6863-6871	in-plane	_
33-31	6872-6882	resolution	_
33-32	6883-6888	3.125	_
33-33	6889-6891	mm	_
33-34	6892-6893	,	_
33-35	6894-6899	slice	_
33-36	6900-6909	thickness	_
33-37	6910-6911	5	_
33-38	6912-6914	mm	_
33-39	6915-6916	,	_
33-40	6917-6919	23	_
33-41	6920-6930	contiguous	_
33-42	6931-6937	slices	_
33-43	6938-6945	aligned	_
33-44	6946-6948	to	_
33-45	6949-6954	AC-PC	_
33-46	6955-6960	plane	_
33-47	6961-6962	)	_
33-48	6963-6964	.	_

Text=The fMRI task consisted of presentation of negative valence/high arousal (e.g.
34-1	6965-6968	The	_
34-2	6969-6973	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
34-3	6974-6978	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
34-4	6979-6988	consisted	_
34-5	6989-6991	of	_
34-6	6992-7004	presentation	_
34-7	7005-7007	of	_
34-8	7008-7016	negative	_
34-9	7017-7029	valence/high	_
34-10	7030-7037	arousal	_
34-11	7038-7039	(	_
34-12	7040-7043	e.g	_
34-13	7044-7045	.	_

Text=snake, car accident, burial, gun, bomb, tornado), neutral valence/low arousal (e.g.
35-1	7046-7051	snake	_
35-2	7052-7053	,	_
35-3	7054-7057	car	_
35-4	7058-7066	accident	_
35-5	7067-7068	,	_
35-6	7069-7075	burial	_
35-7	7076-7077	,	_
35-8	7078-7081	gun	_
35-9	7082-7083	,	_
35-10	7084-7088	bomb	_
35-11	7089-7090	,	_
35-12	7091-7098	tornado	_
35-13	7099-7100	)	_
35-14	7101-7102	,	_
35-15	7103-7110	neutral	_
35-16	7111-7122	valence/low	_
35-17	7123-7130	arousal	_
35-18	7131-7132	(	_
35-19	7133-7136	e.g	_
35-20	7137-7138	.	_

Text=plant, umbrella, office, mushrooms, stool, bus), and fixation images (Fourier transformations of the neutral valence/low arousal images), that we adapted for fMRI use based on quantitative psychophysiologic ratings from the International Affective Picture System (IAPS).
36-1	7139-7144	plant	_
36-2	7145-7146	,	_
36-3	7147-7155	umbrella	_
36-4	7156-7157	,	_
36-5	7158-7164	office	_
36-6	7165-7166	,	_
36-7	7167-7176	mushrooms	_
36-8	7177-7178	,	_
36-9	7179-7184	stool	_
36-10	7185-7186	,	_
36-11	7187-7190	bus	_
36-12	7191-7192	)	_
36-13	7193-7194	,	_
36-14	7195-7198	and	_
36-15	7199-7207	fixation	_
36-16	7208-7214	images	_
36-17	7215-7216	(	_
36-18	7217-7224	Fourier	_
36-19	7225-7240	transformations	_
36-20	7241-7243	of	_
36-21	7244-7247	the	_
36-22	7248-7255	neutral	_
36-23	7256-7267	valence/low	_
36-24	7268-7275	arousal	_
36-25	7276-7282	images	_
36-26	7283-7284	)	_
36-27	7285-7286	,	_
36-28	7287-7291	that	_
36-29	7292-7294	we	_
36-30	7295-7302	adapted	_
36-31	7303-7306	for	_
36-32	7307-7311	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-33	7312-7315	use	_
36-34	7316-7321	based	_
36-35	7322-7324	on	_
36-36	7325-7337	quantitative	_
36-37	7338-7355	psychophysiologic	_
36-38	7356-7363	ratings	_
36-39	7364-7368	from	_
36-40	7369-7372	the	_
36-41	7373-7386	International	_
36-42	7387-7396	Affective	_
36-43	7397-7404	Picture	_
36-44	7405-7411	System	_
36-45	7412-7413	(	_
36-46	7414-7418	IAPS	_
36-47	7419-7420	)	_
36-48	7421-7422	.	_

Text=The IAPS is a well-known set of images with demonstrated reliability and validity, known to invoke brain circuitry associated with negative affective stimuli, HPA hormone responses, and behavior.
37-1	7423-7426	The	_
37-2	7427-7431	IAPS	_
37-3	7432-7434	is	_
37-4	7435-7436	a	_
37-5	7437-7447	well-known	_
37-6	7448-7451	set	_
37-7	7452-7454	of	_
37-8	7455-7461	images	_
37-9	7462-7466	with	_
37-10	7467-7479	demonstrated	_
37-11	7480-7491	reliability	_
37-12	7492-7495	and	_
37-13	7496-7504	validity	_
37-14	7505-7506	,	_
37-15	7507-7512	known	_
37-16	7513-7515	to	_
37-17	7516-7522	invoke	_
37-18	7523-7528	brain	_
37-19	7529-7538	circuitry	_
37-20	7539-7549	associated	_
37-21	7550-7554	with	_
37-22	7555-7563	negative	_
37-23	7564-7573	affective	_
37-24	7574-7581	stimuli	_
37-25	7582-7583	,	_
37-26	7584-7587	HPA	_
37-27	7588-7595	hormone	_
37-28	7596-7605	responses	_
37-29	7606-7607	,	_
37-30	7608-7611	and	_
37-31	7612-7620	behavior	_
37-32	7621-7622	.	_

Text=Our fMRI-adapted IAPS task lasted approximately 18 minutes (3 runs, 6 minutes each).
38-1	7623-7626	Our	_
38-2	7627-7639	fMRI-adapted	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
38-3	7640-7644	IAPS	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
38-4	7645-7649	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
38-5	7650-7656	lasted	_
38-6	7657-7670	approximately	_
38-7	7671-7673	18	_
38-8	7674-7681	minutes	_
38-9	7682-7683	(	_
38-10	7684-7685	3	_
38-11	7686-7690	runs	_
38-12	7691-7692	,	_
38-13	7693-7694	6	_
38-14	7695-7702	minutes	_
38-15	7703-7707	each	_
38-16	7708-7709	)	_
38-17	7710-7711	.	_

Text=Each run contained a total of 72 images ordered in non-randomized blocks of fixation, negative and neutral images.
39-1	7712-7716	Each	_
39-2	7717-7720	run	_
39-3	7721-7730	contained	_
39-4	7731-7732	a	_
39-5	7733-7738	total	_
39-6	7739-7741	of	_
39-7	7742-7744	72	_
39-8	7745-7751	images	_
39-9	7752-7759	ordered	_
39-10	7760-7762	in	_
39-11	7763-7777	non-randomized	_
39-12	7778-7784	blocks	_
39-13	7785-7787	of	_
39-14	7788-7796	fixation	_
39-15	7797-7798	,	_
39-16	7799-7807	negative	_
39-17	7808-7811	and	_
39-18	7812-7819	neutral	_
39-19	7820-7826	images	_
39-20	7827-7828	.	_

Text=Each block of stimuli consisted of 6 images, each presented for 5 seconds.
40-1	7829-7833	Each	_
40-2	7834-7839	block	_
40-3	7840-7842	of	_
40-4	7843-7850	stimuli	_
40-5	7851-7860	consisted	_
40-6	7861-7863	of	http://maven.renci.org/NeuroBridge/neurobridge#QualityOfLifeQuestionnaire
40-7	7864-7865	6	_
40-8	7866-7872	images	_
40-9	7873-7874	,	_
40-10	7875-7879	each	_
40-11	7880-7889	presented	_
40-12	7890-7893	for	_
40-13	7894-7895	5	_
40-14	7896-7903	seconds	_
40-15	7904-7905	.	_

Text=(The specific IAPS images are provided in Supplementary methods.)
41-1	7906-7907	(	_
41-2	7908-7911	The	_
41-3	7912-7920	specific	_
41-4	7921-7925	IAPS	_
41-5	7926-7932	images	_
41-6	7933-7936	are	_
41-7	7937-7945	provided	_
41-8	7946-7948	in	_
41-9	7949-7962	Supplementary	_
41-10	7963-7970	methods	_
41-11	7971-7972	.	_
41-12	7973-7974	)	_

Text=The mean normative valence and arousal of the negative valence/high arousal images was 2.19 (SD=0.48) and 6.35 (SD=0.52), respectively.
42-1	7975-7978	The	_
42-2	7979-7983	mean	_
42-3	7984-7993	normative	_
42-4	7994-8001	valence	_
42-5	8002-8005	and	_
42-6	8006-8013	arousal	_
42-7	8014-8016	of	_
42-8	8017-8020	the	_
42-9	8021-8029	negative	_
42-10	8030-8042	valence/high	_
42-11	8043-8050	arousal	_
42-12	8051-8057	images	_
42-13	8058-8061	was	_
42-14	8062-8066	2.19	_
42-15	8067-8068	(	_
42-16	8069-8076	SD=0.48	_
42-17	8077-8078	)	_
42-18	8079-8082	and	_
42-19	8083-8087	6.35	_
42-20	8088-8089	(	_
42-21	8090-8097	SD=0.52	_
42-22	8098-8099	)	_
42-23	8100-8101	,	_
42-24	8102-8114	respectively	_
42-25	8115-8116	.	_

Text=The mean normative valence and arousal of the neutral valence/low arousal images was 4.90 (SD=0.37) and 2.91 (SD=0.40), respectively.
43-1	8117-8120	The	_
43-2	8121-8125	mean	_
43-3	8126-8135	normative	_
43-4	8136-8143	valence	_
43-5	8144-8147	and	_
43-6	8148-8155	arousal	_
43-7	8156-8158	of	_
43-8	8159-8162	the	_
43-9	8163-8170	neutral	_
43-10	8171-8182	valence/low	_
43-11	8183-8190	arousal	_
43-12	8191-8197	images	_
43-13	8198-8201	was	_
43-14	8202-8206	4.90	_
43-15	8207-8208	(	_
43-16	8209-8216	SD=0.37	_
43-17	8217-8218	)	_
43-18	8219-8222	and	_
43-19	8223-8227	2.91	_
43-20	8228-8229	(	_
43-21	8230-8237	SD=0.40	_
43-22	8238-8239	)	_
43-23	8240-8241	,	_
43-24	8242-8254	respectively	_
43-25	8255-8256	.	_

Text=To ensure attention, participants pressed a button when each new image appeared.
44-1	8257-8259	To	_
44-2	8260-8266	ensure	_
44-3	8267-8276	attention	_
44-4	8277-8278	,	_
44-5	8279-8291	participants	_
44-6	8292-8299	pressed	_
44-7	8300-8301	a	_
44-8	8302-8308	button	_
44-9	8309-8313	when	_
44-10	8314-8318	each	_
44-11	8319-8322	new	_
44-12	8323-8328	image	_
44-13	8329-8337	appeared	_
44-14	8338-8339	.	_

Text=No cognitive task was required to respond to these images, thus responses were unconfounded by cognitive capacities.
45-1	8340-8342	No	_
45-2	8343-8352	cognitive	_
45-3	8353-8357	task	_
45-4	8358-8361	was	_
45-5	8362-8370	required	_
45-6	8371-8373	to	_
45-7	8374-8381	respond	_
45-8	8382-8384	to	_
45-9	8385-8390	these	_
45-10	8391-8397	images	_
45-11	8398-8399	,	_
45-12	8400-8404	thus	_
45-13	8405-8414	responses	_
45-14	8415-8419	were	_
45-15	8420-8432	unconfounded	_
45-16	8433-8435	by	_
45-17	8436-8445	cognitive	_
45-18	8446-8456	capacities	_
45-19	8457-8458	.	_

Text=After the fMRI session, participants saw 8 neutral and 8 negative images, chosen from those presented during the fMRI task, and reported their subjective evaluation of image valence and arousal using the Self-assessment Manikin (SAM).
46-1	8459-8464	After	_
46-2	8465-8468	the	_
46-3	8469-8473	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
46-4	8474-8481	session	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
46-5	8482-8483	,	_
46-6	8484-8496	participants	_
46-7	8497-8500	saw	_
46-8	8501-8502	8	_
46-9	8503-8510	neutral	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
46-10	8511-8514	and	_
46-11	8515-8516	8	_
46-12	8517-8525	negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
46-13	8526-8532	images	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
46-14	8533-8534	,	_
46-15	8535-8541	chosen	_
46-16	8542-8546	from	_
46-17	8547-8552	those	_
46-18	8553-8562	presented	_
46-19	8563-8569	during	_
46-20	8570-8573	the	_
46-21	8574-8578	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
46-22	8579-8583	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
46-23	8584-8585	,	_
46-24	8586-8589	and	_
46-25	8590-8598	reported	_
46-26	8599-8604	their	_
46-27	8605-8615	subjective	_
46-28	8616-8626	evaluation	_
46-29	8627-8629	of	_
46-30	8630-8635	image	_
46-31	8636-8643	valence	_
46-32	8644-8647	and	_
46-33	8648-8655	arousal	_
46-34	8656-8661	using	_
46-35	8662-8665	the	_
46-36	8666-8681	Self-assessment	http://maven.renci.org/NeuroBridge/neurobridge#FamilyHistoryAssessmentModule
46-37	8682-8689	Manikin	http://maven.renci.org/NeuroBridge/neurobridge#FamilyHistoryAssessmentModule
46-38	8690-8691	(	http://maven.renci.org/NeuroBridge/neurobridge#FamilyHistoryAssessmentModule
46-39	8692-8695	SAM	http://maven.renci.org/NeuroBridge/neurobridge#FamilyHistoryAssessmentModule
46-40	8696-8697	)	http://maven.renci.org/NeuroBridge/neurobridge#FamilyHistoryAssessmentModule
46-41	8698-8699	.	_

Text=For details on the experimental task, see.
47-1	8700-8703	For	_
47-2	8704-8711	details	_
47-3	8712-8714	on	_
47-4	8715-8718	the	_
47-5	8719-8731	experimental	_
47-6	8732-8736	task	_
47-7	8737-8738	,	_
47-8	8739-8742	see	_
47-9	8743-8744	.	_

Text=Analysis of fMRI data Data were preprocessed and analyzed using SPM8.
48-1	8745-8753	Analysis	_
48-2	8754-8756	of	_
48-3	8757-8761	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
48-4	8762-8766	data	_
48-5	8767-8771	Data	_
48-6	8772-8776	were	_
48-7	8777-8789	preprocessed	_
48-8	8790-8793	and	_
48-9	8794-8802	analyzed	_
48-10	8803-8808	using	_
48-11	8809-8813	SPM8	_
48-12	8814-8815	.	_

Text=Non-linear volume-based normalization used the MNI152 brain template and spatial smoothing with 6 mm FWHM Gaussian filter, which was then re-sampled to 3 mm isotropic.
49-1	8816-8826	Non-linear	_
49-2	8827-8839	volume-based	_
49-3	8840-8853	normalization	_
49-4	8854-8858	used	_
49-5	8859-8862	the	_
49-6	8863-8869	MNI152	_
49-7	8870-8875	brain	_
49-8	8876-8884	template	_
49-9	8885-8888	and	_
49-10	8889-8896	spatial	_
49-11	8897-8906	smoothing	_
49-12	8907-8911	with	_
49-13	8912-8913	6	_
49-14	8914-8916	mm	_
49-15	8917-8921	FWHM	_
49-16	8922-8930	Gaussian	_
49-17	8931-8937	filter	_
49-18	8938-8939	,	_
49-19	8940-8945	which	_
49-20	8946-8949	was	_
49-21	8950-8954	then	_
49-22	8955-8965	re-sampled	_
49-23	8966-8968	to	_
49-24	8969-8970	3	_
49-25	8971-8973	mm	_
49-26	8974-8983	isotropic	_
49-27	8984-8985	.	_

Text=Outliers in global mean image time series (threshold: 3.5 SDs from the mean) and movement (threshold: 0.7 mm, measured as scan-to-scan movement, separately for translation and rotation) were detected using an artifact detection toolbox (ART) and entered as nuisance regressors in the first-level, single-subject general linear model (GLM).
50-1	8986-8994	Outliers	_
50-2	8995-8997	in	_
50-3	8998-9004	global	_
50-4	9005-9009	mean	_
50-5	9010-9015	image	_
50-6	9016-9020	time	_
50-7	9021-9027	series	_
50-8	9028-9029	(	_
50-9	9030-9039	threshold	_
50-10	9040-9041	:	_
50-11	9042-9045	3.5	_
50-12	9046-9049	SDs	_
50-13	9050-9054	from	_
50-14	9055-9058	the	_
50-15	9059-9063	mean	_
50-16	9064-9065	)	_
50-17	9066-9069	and	_
50-18	9070-9078	movement	_
50-19	9079-9080	(	_
50-20	9081-9090	threshold	_
50-21	9091-9092	:	_
50-22	9093-9096	0.7	_
50-23	9097-9099	mm	_
50-24	9100-9101	,	_
50-25	9102-9110	measured	_
50-26	9111-9113	as	_
50-27	9114-9126	scan-to-scan	_
50-28	9127-9135	movement	_
50-29	9136-9137	,	_
50-30	9138-9148	separately	_
50-31	9149-9152	for	_
50-32	9153-9164	translation	_
50-33	9165-9168	and	_
50-34	9169-9177	rotation	_
50-35	9178-9179	)	_
50-36	9180-9184	were	_
50-37	9185-9193	detected	_
50-38	9194-9199	using	_
50-39	9200-9202	an	_
50-40	9203-9211	artifact	_
50-41	9212-9221	detection	_
50-42	9222-9229	toolbox	_
50-43	9230-9231	(	_
50-44	9232-9235	ART	_
50-45	9236-9237	)	_
50-46	9238-9241	and	_
50-47	9242-9249	entered	_
50-48	9250-9252	as	_
50-49	9253-9261	nuisance	_
50-50	9262-9272	regressors	_
50-51	9273-9275	in	_
50-52	9276-9279	the	_
50-53	9280-9291	first-level	_
50-54	9292-9293	,	_
50-55	9294-9308	single-subject	_
50-56	9309-9316	general	_
50-57	9317-9323	linear	_
50-58	9324-9329	model	_
50-59	9330-9331	(	_
50-60	9332-9335	GLM	_
50-61	9336-9337	)	_
50-62	9338-9339	.	_

Text=Masks excluding voxels outside the brain were applied to ensure that voxels in regions with high inter-participant variability in signal drop-out (e.g.
51-1	9340-9345	Masks	_
51-2	9346-9355	excluding	_
51-3	9356-9362	voxels	_
51-4	9363-9370	outside	_
51-5	9371-9374	the	_
51-6	9375-9380	brain	_
51-7	9381-9385	were	_
51-8	9386-9393	applied	_
51-9	9394-9396	to	_
51-10	9397-9403	ensure	_
51-11	9404-9408	that	_
51-12	9409-9415	voxels	_
51-13	9416-9418	in	_
51-14	9419-9426	regions	_
51-15	9427-9431	with	_
51-16	9432-9436	high	_
51-17	9437-9454	inter-participant	_
51-18	9455-9466	variability	_
51-19	9467-9469	in	_
51-20	9470-9476	signal	_
51-21	9477-9485	drop-out	_
51-22	9486-9487	(	_
51-23	9488-9491	e.g	_
51-24	9492-9493	.	_

Text=OFC) were not arbitrarily excluded.
52-1	9494-9497	OFC	_
52-2	9498-9499	)	_
52-3	9500-9504	were	_
52-4	9505-9508	not	_
52-5	9509-9520	arbitrarily	_
52-6	9521-9529	excluded	_
52-7	9530-9531	.	_

Text=Comparisons of interest (negative> neutral) from the first-level, single-subject analyses were tested using linear contrasts and SPM t-maps.
53-1	9532-9543	Comparisons	_
53-2	9544-9546	of	_
53-3	9547-9555	interest	_
53-4	9556-9557	(	_
53-5	9558-9566	negative	_
53-6	9567-9568	>	_
53-7	9569-9576	neutral	_
53-8	9577-9578	)	_
53-9	9579-9583	from	_
53-10	9584-9587	the	_
53-11	9588-9599	first-level	_
53-12	9600-9601	,	_
53-13	9602-9616	single-subject	_
53-14	9617-9625	analyses	_
53-15	9626-9630	were	_
53-16	9631-9637	tested	_
53-17	9638-9643	using	_
53-18	9644-9650	linear	_
53-19	9651-9660	contrasts	_
53-20	9661-9664	and	_
53-21	9665-9668	SPM	_
53-22	9669-9675	t-maps	_
53-23	9676-9677	.	_

Text=Outputs from the first-level, single-subject analyses were submitted to second-level random effects analysis (see below).
54-1	9678-9685	Outputs	_
54-2	9686-9690	from	_
54-3	9691-9694	the	_
54-4	9695-9706	first-level	_
54-5	9707-9708	,	_
54-6	9709-9723	single-subject	_
54-7	9724-9732	analyses	_
54-8	9733-9737	were	_
54-9	9738-9747	submitted	_
54-10	9748-9750	to	_
54-11	9751-9763	second-level	_
54-12	9764-9770	random	_
54-13	9771-9778	effects	_
54-14	9779-9787	analysis	_
54-15	9788-9789	(	_
54-16	9790-9793	see	_
54-17	9794-9799	below	_
54-18	9800-9801	)	_
54-19	9802-9803	.	_

Text=BOLD-response analysis One-sample t-test examined the BOLD signal responses to negative> neutral stimuli across the full sample (n=99), with a whole-brain, voxel-wise family-wise error (FWE) -corrected threshold of p <0.05.
55-1	9804-9817	BOLD-response	_
55-2	9818-9826	analysis	_
55-3	9827-9837	One-sample	_
55-4	9838-9844	t-test	_
55-5	9845-9853	examined	_
55-6	9854-9857	the	_
55-7	9858-9862	BOLD	_
55-8	9863-9869	signal	_
55-9	9870-9879	responses	_
55-10	9880-9882	to	_
55-11	9883-9891	negative	_
55-12	9892-9893	>	_
55-13	9894-9901	neutral	_
55-14	9902-9909	stimuli	_
55-15	9910-9916	across	_
55-16	9917-9920	the	_
55-17	9921-9925	full	_
55-18	9926-9932	sample	_
55-19	9933-9934	(	_
55-20	9935-9939	n=99	_
55-21	9940-9941	)	_
55-22	9942-9943	,	_
55-23	9944-9948	with	_
55-24	9949-9950	a	_
55-25	9951-9962	whole-brain	_
55-26	9963-9964	,	_
55-27	9965-9975	voxel-wise	_
55-28	9976-9987	family-wise	_
55-29	9988-9993	error	_
55-30	9994-9995	(	_
55-31	9996-9999	FWE	_
55-32	10000-10001	)	_
55-33	10002-10012	-corrected	_
55-34	10013-10022	threshold	_
55-35	10023-10025	of	_
55-36	10026-10027	p	_
55-37	10028-10029	<	_
55-38	10030-10034	0.05	_
55-39	10035-10036	.	_

Text=Next, an intersection analysis performed using MarsBaR (Brett et al., 2002), identified clusters with whole-brain, voxel-wise FWE-corrected p <0.05 threshold that were conjointly located within anatomic boundaries of PAG, HYPO, AMYG, HIPP, OFC, ACC, and mPFC (anatomical masks defined using a manually segmented MNI-152 brain template).
56-1	10037-10041	Next	_
56-2	10042-10043	,	_
56-3	10044-10046	an	_
56-4	10047-10059	intersection	_
56-5	10060-10068	analysis	_
56-6	10069-10078	performed	_
56-7	10079-10084	using	_
56-8	10085-10092	MarsBaR	_
56-9	10093-10094	(	_
56-10	10095-10100	Brett	_
56-11	10101-10103	et	_
56-12	10104-10107	al.	_
56-13	10108-10109	,	_
56-14	10110-10114	2002	_
56-15	10115-10116	)	_
56-16	10117-10118	,	_
56-17	10119-10129	identified	_
56-18	10130-10138	clusters	_
56-19	10139-10143	with	_
56-20	10144-10155	whole-brain	_
56-21	10156-10157	,	_
56-22	10158-10168	voxel-wise	_
56-23	10169-10182	FWE-corrected	_
56-24	10183-10184	p	_
56-25	10185-10186	<	_
56-26	10187-10191	0.05	_
56-27	10192-10201	threshold	_
56-28	10202-10206	that	_
56-29	10207-10211	were	_
56-30	10212-10222	conjointly	_
56-31	10223-10230	located	_
56-32	10231-10237	within	_
56-33	10238-10246	anatomic	_
56-34	10247-10257	boundaries	_
56-35	10258-10260	of	_
56-36	10261-10264	PAG	_
56-37	10265-10266	,	_
56-38	10267-10271	HYPO	_
56-39	10272-10273	,	_
56-40	10274-10278	AMYG	_
56-41	10279-10280	,	_
56-42	10281-10285	HIPP	_
56-43	10286-10287	,	_
56-44	10288-10291	OFC	_
56-45	10292-10293	,	_
56-46	10294-10297	ACC	_
56-47	10298-10299	,	_
56-48	10300-10303	and	_
56-49	10304-10308	mPFC	_
56-50	10309-10310	(	_
56-51	10311-10321	anatomical	_
56-52	10322-10327	masks	_
56-53	10328-10335	defined	_
56-54	10336-10341	using	_
56-55	10342-10343	a	_
56-56	10344-10352	manually	_
56-57	10353-10362	segmented	_
56-58	10363-10370	MNI-152	_
56-59	10371-10376	brain	_
56-60	10377-10385	template	_
56-61	10386-10387	)	_
56-62	10388-10389	.	_

Text=Given the small volumes and midline location of the PAG and HYPO, single regions of interest (ROIs) combining right and left hemispheres were used for each of these two regions; remaining ROI masks were bilateral.
57-1	10390-10395	Given	_
57-2	10396-10399	the	_
57-3	10400-10405	small	_
57-4	10406-10413	volumes	_
57-5	10414-10417	and	_
57-6	10418-10425	midline	_
57-7	10426-10434	location	_
57-8	10435-10437	of	_
57-9	10438-10441	the	_
57-10	10442-10445	PAG	_
57-11	10446-10449	and	_
57-12	10450-10454	HYPO	_
57-13	10455-10456	,	_
57-14	10457-10463	single	_
57-15	10464-10471	regions	_
57-16	10472-10474	of	_
57-17	10475-10483	interest	_
57-18	10484-10485	(	_
57-19	10486-10490	ROIs	_
57-20	10491-10492	)	_
57-21	10493-10502	combining	_
57-22	10503-10508	right	_
57-23	10509-10512	and	_
57-24	10513-10517	left	_
57-25	10518-10529	hemispheres	_
57-26	10530-10534	were	_
57-27	10535-10539	used	_
57-28	10540-10543	for	_
57-29	10544-10548	each	_
57-30	10549-10551	of	_
57-31	10552-10557	these	_
57-32	10558-10561	two	_
57-33	10562-10569	regions	_
57-34	10570-10571	;	_
57-35	10572-10581	remaining	_
57-36	10582-10585	ROI	_
57-37	10586-10591	masks	_
57-38	10592-10596	were	_
57-39	10597-10606	bilateral	_
57-40	10607-10608	.	_

Text=Average parameter estimates (percent signal change values) within each ROI were extracted for each participant using REX and exported into JMP (SAS Institute, Cary, NC, USA), which was used for all remaining BOLD response analyses.
58-1	10609-10616	Average	_
58-2	10617-10626	parameter	_
58-3	10627-10636	estimates	_
58-4	10637-10638	(	_
58-5	10639-10646	percent	_
58-6	10647-10653	signal	_
58-7	10654-10660	change	_
58-8	10661-10667	values	_
58-9	10668-10669	)	_
58-10	10670-10676	within	_
58-11	10677-10681	each	_
58-12	10682-10685	ROI	_
58-13	10686-10690	were	_
58-14	10691-10700	extracted	_
58-15	10701-10704	for	_
58-16	10705-10709	each	_
58-17	10710-10721	participant	_
58-18	10722-10727	using	_
58-19	10728-10731	REX	_
58-20	10732-10735	and	_
58-21	10736-10744	exported	_
58-22	10745-10749	into	_
58-23	10750-10753	JMP	_
58-24	10754-10755	(	_
58-25	10756-10759	SAS	_
58-26	10760-10769	Institute	_
58-27	10770-10771	,	_
58-28	10772-10776	Cary	_
58-29	10777-10778	,	_
58-30	10779-10781	NC	_
58-31	10782-10783	,	_
58-32	10784-10787	USA	_
58-33	10788-10789	)	_
58-34	10790-10791	,	_
58-35	10792-10797	which	_
58-36	10798-10801	was	_
58-37	10802-10806	used	_
58-38	10807-10810	for	_
58-39	10811-10814	all	_
58-40	10815-10824	remaining	_
58-41	10825-10829	BOLD	_
58-42	10830-10838	response	_
58-43	10839-10847	analyses	_
58-44	10848-10849	.	_

Text=Activity of the negative affective circuitry, operationalized as parameter estimates identified and extracted as described above, was then explored as a function of Dysphoric Mood State using regression analysis to identify main effects and interactions with sex, significant at p <0.05 level.
59-1	10850-10858	Activity	_
59-2	10859-10861	of	_
59-3	10862-10865	the	_
59-4	10866-10874	negative	_
59-5	10875-10884	affective	_
59-6	10885-10894	circuitry	_
59-7	10895-10896	,	_
59-8	10897-10912	operationalized	_
59-9	10913-10915	as	_
59-10	10916-10925	parameter	_
59-11	10926-10935	estimates	_
59-12	10936-10946	identified	_
59-13	10947-10950	and	_
59-14	10951-10960	extracted	_
59-15	10961-10963	as	_
59-16	10964-10973	described	_
59-17	10974-10979	above	_
59-18	10980-10981	,	_
59-19	10982-10985	was	_
59-20	10986-10990	then	_
59-21	10991-10999	explored	_
59-22	11000-11002	as	_
59-23	11003-11004	a	_
59-24	11005-11013	function	_
59-25	11014-11016	of	_
59-26	11017-11026	Dysphoric	_
59-27	11027-11031	Mood	_
59-28	11032-11037	State	_
59-29	11038-11043	using	_
59-30	11044-11054	regression	_
59-31	11055-11063	analysis	_
59-32	11064-11066	to	_
59-33	11067-11075	identify	_
59-34	11076-11080	main	_
59-35	11081-11088	effects	_
59-36	11089-11092	and	_
59-37	11093-11105	interactions	_
59-38	11106-11110	with	_
59-39	11111-11114	sex	_
59-40	11115-11116	,	_
59-41	11117-11128	significant	_
59-42	11129-11131	at	_
59-43	11132-11133	p	_
59-44	11134-11135	<	_
59-45	11136-11140	0.05	_
59-46	11141-11146	level	_
59-47	11147-11148	.	_

Text=Finally, although not the main focus of this paper, regression models were re-run with the inclusion of diagnostic case status (no history of MDD/SCZ; history of MDD/SCZ) and psychotropic medication status (no current psychotropic medication; current use of psychotropic medication) in the models to explore the potential impact of these factors on BOLD activity.
60-1	11149-11156	Finally	_
60-2	11157-11158	,	_
60-3	11159-11167	although	_
60-4	11168-11171	not	_
60-5	11172-11175	the	_
60-6	11176-11180	main	_
60-7	11181-11186	focus	_
60-8	11187-11189	of	_
60-9	11190-11194	this	_
60-10	11195-11200	paper	_
60-11	11201-11202	,	_
60-12	11203-11213	regression	_
60-13	11214-11220	models	_
60-14	11221-11225	were	_
60-15	11226-11232	re-run	_
60-16	11233-11237	with	_
60-17	11238-11241	the	_
60-18	11242-11251	inclusion	_
60-19	11252-11254	of	_
60-20	11255-11265	diagnostic	_
60-21	11266-11270	case	_
60-22	11271-11277	status	_
60-23	11278-11279	(	_
60-24	11280-11282	no	_
60-25	11283-11290	history	_
60-26	11291-11293	of	_
60-27	11294-11301	MDD/SCZ	_
60-28	11302-11303	;	_
60-29	11304-11311	history	_
60-30	11312-11314	of	_
60-31	11315-11322	MDD/SCZ	_
60-32	11323-11324	)	_
60-33	11325-11328	and	_
60-34	11329-11341	psychotropic	_
60-35	11342-11352	medication	_
60-36	11353-11359	status	_
60-37	11360-11361	(	_
60-38	11362-11364	no	_
60-39	11365-11372	current	_
60-40	11373-11385	psychotropic	_
60-41	11386-11396	medication	_
60-42	11397-11398	;	_
60-43	11399-11406	current	_
60-44	11407-11410	use	_
60-45	11411-11413	of	_
60-46	11414-11426	psychotropic	_
60-47	11427-11437	medication	_
60-48	11438-11439	)	_
60-49	11440-11442	in	_
60-50	11443-11446	the	_
60-51	11447-11453	models	_
60-52	11454-11456	to	_
60-53	11457-11464	explore	_
60-54	11465-11468	the	_
60-55	11469-11478	potential	_
60-56	11479-11485	impact	_
60-57	11486-11488	of	_
60-58	11489-11494	these	_
60-59	11495-11502	factors	_
60-60	11503-11505	on	_
60-61	11506-11510	BOLD	_
60-62	11511-11519	activity	_
60-63	11520-11521	.	_

Text=Functional connectivity analysis Similar to BOLD response analyses above, we assessed task-related connectivity using generalized psychophysiological interaction (gPPI).
61-1	11522-11532	Functional	_
61-2	11533-11545	connectivity	_
61-3	11546-11554	analysis	_
61-4	11555-11562	Similar	_
61-5	11563-11565	to	_
61-6	11566-11570	BOLD	_
61-7	11571-11579	response	_
61-8	11580-11588	analyses	_
61-9	11589-11594	above	_
61-10	11595-11596	,	_
61-11	11597-11599	we	_
61-12	11600-11608	assessed	_
61-13	11609-11621	task-related	_
61-14	11622-11634	connectivity	_
61-15	11635-11640	using	_
61-16	11641-11652	generalized	_
61-17	11653-11672	psychophysiological	_
61-18	11673-11684	interaction	_
61-19	11685-11686	(	_
61-20	11687-11691	gPPI	_
61-21	11692-11693	)	_
61-22	11694-11695	.	_

Text=Time courses from seed ROIs (defined as above: clusters from the BOLD-anatomic ROI intersection analyses in MarsBaR) were extracted and added to two additional PPI regressors (interaction of the seed time course with regressors for negative and neutral content) to individual subject-level GLMs.
62-1	11696-11700	Time	_
62-2	11701-11708	courses	_
62-3	11709-11713	from	_
62-4	11714-11718	seed	_
62-5	11719-11723	ROIs	_
62-6	11724-11725	(	_
62-7	11726-11733	defined	_
62-8	11734-11736	as	_
62-9	11737-11742	above	_
62-10	11743-11744	:	_
62-11	11745-11753	clusters	_
62-12	11754-11758	from	_
62-13	11759-11762	the	_
62-14	11763-11776	BOLD-anatomic	_
62-15	11777-11780	ROI	_
62-16	11781-11793	intersection	_
62-17	11794-11802	analyses	_
62-18	11803-11805	in	_
62-19	11806-11813	MarsBaR	_
62-20	11814-11815	)	_
62-21	11816-11820	were	_
62-22	11821-11830	extracted	_
62-23	11831-11834	and	_
62-24	11835-11840	added	_
62-25	11841-11843	to	_
62-26	11844-11847	two	_
62-27	11848-11858	additional	_
62-28	11859-11862	PPI	_
62-29	11863-11873	regressors	_
62-30	11874-11875	(	_
62-31	11876-11887	interaction	_
62-32	11888-11890	of	_
62-33	11891-11894	the	_
62-34	11895-11899	seed	_
62-35	11900-11904	time	_
62-36	11905-11911	course	_
62-37	11912-11916	with	_
62-38	11917-11927	regressors	_
62-39	11928-11931	for	_
62-40	11932-11940	negative	_
62-41	11941-11944	and	_
62-42	11945-11952	neutral	_
62-43	11953-11960	content	_
62-44	11961-11962	)	_
62-45	11963-11965	to	_
62-46	11966-11976	individual	_
62-47	11977-11990	subject-level	_
62-48	11991-11995	GLMs	_
62-49	11996-11997	.	_

Text=These interaction regressors were orthogonal to the task and seed regressors, ensuring that the seed ROI activation and PPI connectivity were independent.
63-1	11998-12003	These	_
63-2	12004-12015	interaction	_
63-3	12016-12026	regressors	_
63-4	12027-12031	were	_
63-5	12032-12042	orthogonal	_
63-6	12043-12045	to	_
63-7	12046-12049	the	_
63-8	12050-12054	task	_
63-9	12055-12058	and	_
63-10	12059-12063	seed	_
63-11	12064-12074	regressors	_
63-12	12075-12076	,	_
63-13	12077-12085	ensuring	_
63-14	12086-12090	that	_
63-15	12091-12094	the	_
63-16	12095-12099	seed	_
63-17	12100-12103	ROI	_
63-18	12104-12114	activation	_
63-19	12115-12118	and	_
63-20	12119-12122	PPI	_
63-21	12123-12135	connectivity	_
63-22	12136-12140	were	_
63-23	12141-12152	independent	_
63-24	12153-12154	.	_

Text=Connectivity was measured at single-subject level by estimating the difference between the interaction of the seed timecourse with the regressor for negative compared with neutral stimuli, conducted separately for each ROI.
64-1	12155-12167	Connectivity	_
64-2	12168-12171	was	_
64-3	12172-12180	measured	_
64-4	12181-12183	at	_
64-5	12184-12198	single-subject	_
64-6	12199-12204	level	_
64-7	12205-12207	by	_
64-8	12208-12218	estimating	_
64-9	12219-12222	the	_
64-10	12223-12233	difference	_
64-11	12234-12241	between	_
64-12	12242-12245	the	_
64-13	12246-12257	interaction	_
64-14	12258-12260	of	_
64-15	12261-12264	the	_
64-16	12265-12269	seed	_
64-17	12270-12280	timecourse	_
64-18	12281-12285	with	_
64-19	12286-12289	the	_
64-20	12290-12299	regressor	_
64-21	12300-12303	for	_
64-22	12304-12312	negative	_
64-23	12313-12321	compared	_
64-24	12322-12326	with	_
64-25	12327-12334	neutral	_
64-26	12335-12342	stimuli	_
64-27	12343-12344	,	_
64-28	12345-12354	conducted	_
64-29	12355-12365	separately	_
64-30	12366-12369	for	_
64-31	12370-12374	each	_
64-32	12375-12378	ROI	_
64-33	12379-12380	.	_

Text=Results of single-subject analysis were entered into second-level random effects analysis to probe group-level changes in connectivity during negative versus neutral condition.
65-1	12381-12388	Results	_
65-2	12389-12391	of	_
65-3	12392-12406	single-subject	_
65-4	12407-12415	analysis	_
65-5	12416-12420	were	_
65-6	12421-12428	entered	_
65-7	12429-12433	into	_
65-8	12434-12446	second-level	_
65-9	12447-12453	random	_
65-10	12454-12461	effects	_
65-11	12462-12470	analysis	_
65-12	12471-12473	to	_
65-13	12474-12479	probe	_
65-14	12480-12491	group-level	_
65-15	12492-12499	changes	_
65-16	12500-12502	in	_
65-17	12503-12515	connectivity	_
65-18	12516-12522	during	_
65-19	12523-12531	negative	_
65-20	12532-12538	versus	_
65-21	12539-12546	neutral	_
65-22	12547-12556	condition	_
65-23	12557-12558	.	_

Text=First, task-related connectivity was assessed across the whole sample, using clusters from subcortical arousal regions (PAG, HYPO, AMYG) as seeds.
66-1	12559-12564	First	_
66-2	12565-12566	,	_
66-3	12567-12579	task-related	_
66-4	12580-12592	connectivity	_
66-5	12593-12596	was	_
66-6	12597-12605	assessed	_
66-7	12606-12612	across	_
66-8	12613-12616	the	_
66-9	12617-12622	whole	_
66-10	12623-12629	sample	_
66-11	12630-12631	,	_
66-12	12632-12637	using	_
66-13	12638-12646	clusters	_
66-14	12647-12651	from	_
66-15	12652-12663	subcortical	_
66-16	12664-12671	arousal	_
66-17	12672-12679	regions	_
66-18	12680-12681	(	_
66-19	12682-12685	PAG	_
66-20	12686-12687	,	_
66-21	12688-12692	HYPO	_
66-22	12693-12694	,	_
66-23	12695-12699	AMYG	_
66-24	12700-12701	)	_
66-25	12702-12704	as	_
66-26	12705-12710	seeds	_
66-27	12711-12712	.	_

Text=These were chosen based on known neuroanatomical connections between these regions and cortical ROIs.
67-1	12713-12718	These	_
67-2	12719-12723	were	_
67-3	12724-12730	chosen	_
67-4	12731-12736	based	_
67-5	12737-12739	on	_
67-6	12740-12745	known	_
67-7	12746-12761	neuroanatomical	_
67-8	12762-12773	connections	_
67-9	12774-12781	between	_
67-10	12782-12787	these	_
67-11	12788-12795	regions	_
67-12	12796-12799	and	_
67-13	12800-12808	cortical	_
67-14	12809-12813	ROIs	_
67-15	12814-12815	.	_

Text=Next, connectivity was explored as a function of Dysphoric Mood State, mirroring BOLD-response analyses and with seed regions chosen from subcortical arousal ROIs that emerged as significant within each parallel analysis at the BOLD-level response.
68-1	12816-12820	Next	_
68-2	12821-12822	,	_
68-3	12823-12835	connectivity	_
68-4	12836-12839	was	_
68-5	12840-12848	explored	_
68-6	12849-12851	as	_
68-7	12852-12853	a	_
68-8	12854-12862	function	_
68-9	12863-12865	of	_
68-10	12866-12875	Dysphoric	_
68-11	12876-12880	Mood	_
68-12	12881-12886	State	_
68-13	12887-12888	,	_
68-14	12889-12898	mirroring	_
68-15	12899-12912	BOLD-response	_
68-16	12913-12921	analyses	_
68-17	12922-12925	and	_
68-18	12926-12930	with	_
68-19	12931-12935	seed	_
68-20	12936-12943	regions	_
68-21	12944-12950	chosen	_
68-22	12951-12955	from	_
68-23	12956-12967	subcortical	_
68-24	12968-12975	arousal	_
68-25	12976-12980	ROIs	_
68-26	12981-12985	that	_
68-27	12986-12993	emerged	_
68-28	12994-12996	as	_
68-29	12997-13008	significant	_
68-30	13009-13015	within	_
68-31	13016-13020	each	_
68-32	13021-13029	parallel	_
68-33	13030-13038	analysis	_
68-34	13039-13041	at	_
68-35	13042-13045	the	_
68-36	13046-13056	BOLD-level	_
68-37	13057-13065	response	_
68-38	13066-13067	.	_

Text=Analyses were then repeated to detect interactions with sex.
69-1	13068-13076	Analyses	_
69-2	13077-13081	were	_
69-3	13082-13086	then	_
69-4	13087-13095	repeated	_
69-5	13096-13098	to	_
69-6	13099-13105	detect	_
69-7	13106-13118	interactions	_
69-8	13119-13123	with	_
69-9	13124-13127	sex	_
69-10	13128-13129	.	_

Text=For these functional connectivity analyses, we used small volume correction (SVC) approach in SPM8, which limits voxel-wise analyses to voxels within a priori hypothesized ROIs.
70-1	13130-13133	For	_
70-2	13134-13139	these	_
70-3	13140-13150	functional	_
70-4	13151-13163	connectivity	_
70-5	13164-13172	analyses	_
70-6	13173-13174	,	_
70-7	13175-13177	we	_
70-8	13178-13182	used	_
70-9	13183-13188	small	_
70-10	13189-13195	volume	_
70-11	13196-13206	correction	_
70-12	13207-13208	(	_
70-13	13209-13212	SVC	_
70-14	13213-13214	)	_
70-15	13215-13223	approach	_
70-16	13224-13226	in	_
70-17	13227-13231	SPM8	_
70-18	13232-13233	,	_
70-19	13234-13239	which	_
70-20	13240-13246	limits	_
70-21	13247-13257	voxel-wise	_
70-22	13258-13266	analyses	_
70-23	13267-13269	to	_
70-24	13270-13276	voxels	_
70-25	13277-13283	within	_
70-26	13284-13285	a	_
70-27	13286-13292	priori	_
70-28	13293-13305	hypothesized	_
70-29	13306-13310	ROIs	_
70-30	13311-13312	.	_

Text=Target ROIs (PAG, HYPO, AMYG, HIPP, OFC, ACC, mPFC) were defined as anatomical masks (manually segmented from MNI-152 brain template, as described above) and implemented as overlays on the SPM8 canonical brain.
71-1	13313-13319	Target	_
71-2	13320-13324	ROIs	_
71-3	13325-13326	(	_
71-4	13327-13330	PAG	_
71-5	13331-13332	,	_
71-6	13333-13337	HYPO	_
71-7	13338-13339	,	_
71-8	13340-13344	AMYG	_
71-9	13345-13346	,	_
71-10	13347-13351	HIPP	_
71-11	13352-13353	,	_
71-12	13354-13357	OFC	_
71-13	13358-13359	,	_
71-14	13360-13363	ACC	_
71-15	13364-13365	,	_
71-16	13366-13370	mPFC	_
71-17	13371-13372	)	_
71-18	13373-13377	were	_
71-19	13378-13385	defined	_
71-20	13386-13388	as	_
71-21	13389-13399	anatomical	_
71-22	13400-13405	masks	_
71-23	13406-13407	(	_
71-24	13408-13416	manually	_
71-25	13417-13426	segmented	_
71-26	13427-13431	from	_
71-27	13432-13439	MNI-152	_
71-28	13440-13445	brain	_
71-29	13446-13454	template	_
71-30	13455-13456	,	_
71-31	13457-13459	as	_
71-32	13460-13469	described	_
71-33	13470-13475	above	_
71-34	13476-13477	)	_
71-35	13478-13481	and	_
71-36	13482-13493	implemented	_
71-37	13494-13496	as	_
71-38	13497-13505	overlays	_
71-39	13506-13508	on	_
71-40	13509-13512	the	_
71-41	13513-13517	SPM8	_
71-42	13518-13527	canonical	_
71-43	13528-13533	brain	_
71-44	13534-13535	.	_

Text=False positives were controlled using FWE-correction: within an anatomical ROI, significant results identified using SVC (initial voxel-wise threshold p <0.05 uncorrected) were reported as significant if they additionally met the peak-level threshold of p <0.05, FWE-corrected.
72-1	13536-13541	False	_
72-2	13542-13551	positives	_
72-3	13552-13556	were	_
72-4	13557-13567	controlled	_
72-5	13568-13573	using	_
72-6	13574-13588	FWE-correction	_
72-7	13589-13590	:	_
72-8	13591-13597	within	_
72-9	13598-13600	an	_
72-10	13601-13611	anatomical	_
72-11	13612-13615	ROI	_
72-12	13616-13617	,	_
72-13	13618-13629	significant	_
72-14	13630-13637	results	_
72-15	13638-13648	identified	_
72-16	13649-13654	using	_
72-17	13655-13658	SVC	_
72-18	13659-13660	(	_
72-19	13661-13668	initial	_
72-20	13669-13679	voxel-wise	_
72-21	13680-13689	threshold	_
72-22	13690-13691	p	_
72-23	13692-13693	<	_
72-24	13694-13698	0.05	_
72-25	13699-13710	uncorrected	_
72-26	13711-13712	)	_
72-27	13713-13717	were	_
72-28	13718-13726	reported	_
72-29	13727-13729	as	_
72-30	13730-13741	significant	_
72-31	13742-13744	if	_
72-32	13745-13749	they	_
72-33	13750-13762	additionally	_
72-34	13763-13766	met	_
72-35	13767-13770	the	_
72-36	13771-13781	peak-level	_
72-37	13782-13791	threshold	_
72-38	13792-13794	of	_
72-39	13795-13796	p	_
72-40	13797-13798	<	_
72-41	13799-13803	0.05	_
72-42	13804-13805	,	_
72-43	13806-13819	FWE-corrected	_
72-44	13820-13821	.	_

Text=Additionally, for calculation of effect sizes and illustrative purposes in figures below, average connectivity values (beta weights of PPI regressors) in significant target clusters were extracted using REX.
73-1	13822-13834	Additionally	_
73-2	13835-13836	,	_
73-3	13837-13840	for	_
73-4	13841-13852	calculation	_
73-5	13853-13855	of	_
73-6	13856-13862	effect	_
73-7	13863-13868	sizes	_
73-8	13869-13872	and	_
73-9	13873-13885	illustrative	_
73-10	13886-13894	purposes	_
73-11	13895-13897	in	_
73-12	13898-13905	figures	_
73-13	13906-13911	below	_
73-14	13912-13913	,	_
73-15	13914-13921	average	_
73-16	13922-13934	connectivity	_
73-17	13935-13941	values	_
73-18	13942-13943	(	_
73-19	13944-13948	beta	_
73-20	13949-13956	weights	_
73-21	13957-13959	of	_
73-22	13960-13963	PPI	_
73-23	13964-13974	regressors	_
73-24	13975-13976	)	_
73-25	13977-13979	in	_
73-26	13980-13991	significant	_
73-27	13992-13998	target	_
73-28	13999-14007	clusters	_
73-29	14008-14012	were	_
73-30	14013-14022	extracted	_
73-31	14023-14028	using	_
73-32	14029-14032	REX	_
73-33	14033-14034	.	_

Text=Furthermore, regression models were re-run with the inclusion of diagnostic case status (no history of MDD/SCZ; history of MDD/SCZ) and psychotropic medication status (no current psychotropic medication; current use of psychotropic medication) in the models to explore the potential impact of these factors on functional connectivity.
74-1	14035-14046	Furthermore	_
74-2	14047-14048	,	_
74-3	14049-14059	regression	_
74-4	14060-14066	models	_
74-5	14067-14071	were	_
74-6	14072-14078	re-run	_
74-7	14079-14083	with	_
74-8	14084-14087	the	_
74-9	14088-14097	inclusion	_
74-10	14098-14100	of	_
74-11	14101-14111	diagnostic	_
74-12	14112-14116	case	_
74-13	14117-14123	status	_
74-14	14124-14125	(	_
74-15	14126-14128	no	_
74-16	14129-14136	history	_
74-17	14137-14139	of	_
74-18	14140-14147	MDD/SCZ	_
74-19	14148-14149	;	_
74-20	14150-14157	history	_
74-21	14158-14160	of	_
74-22	14161-14168	MDD/SCZ	_
74-23	14169-14170	)	_
74-24	14171-14174	and	_
74-25	14175-14187	psychotropic	_
74-26	14188-14198	medication	_
74-27	14199-14205	status	_
74-28	14206-14207	(	_
74-29	14208-14210	no	_
74-30	14211-14218	current	_
74-31	14219-14231	psychotropic	_
74-32	14232-14242	medication	_
74-33	14243-14244	;	_
74-34	14245-14252	current	_
74-35	14253-14256	use	_
74-36	14257-14259	of	_
74-37	14260-14272	psychotropic	_
74-38	14273-14283	medication	_
74-39	14284-14285	)	_
74-40	14286-14288	in	_
74-41	14289-14292	the	_
74-42	14293-14299	models	_
74-43	14300-14302	to	_
74-44	14303-14310	explore	_
74-45	14311-14314	the	_
74-46	14315-14324	potential	_
74-47	14325-14331	impact	_
74-48	14332-14334	of	_
74-49	14335-14340	these	_
74-50	14341-14348	factors	_
74-51	14349-14351	on	_
74-52	14352-14362	functional	_
74-53	14363-14375	connectivity	_
74-54	14376-14377	.	_

